EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea

Yuk Kam Yau, Qi Su, Zhilu Xu, Whitney Tang, Jessica Y L Ching, Joyce Wing Yan Mak, Chun Pan Cheung, Matthew Fung, Margaret Ip, Paul Kay Sheung Chan, Justin Che Yuen Wu, Francis Ka Leung Chan und 1 weitere

Alimentary Pharmacology & Therapeutics · 2023-10 · 58 (8) · 795-804

DOI: 10.1111/apt.17703 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 05.09.2023. Verfasst von Yuk Kam Yau und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Hydrogen Sulfide. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health and Medical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Faecal microbiota transplantation (FMT) has been shown to improve symptoms in a proportion of patients with irritable bowel syndrome (IBS).

Aim

We performed a randomised trial to assess the efficacy of FMT in patients with IBS.

Methods

We randomised 56 patients with diarrhoea‐predominant IBS 1:1 to FMT or placebo via the duodenal route at baseline and week 4. The primary outcome was > 50 points decrease in IBS severity scoring system (IBS‐SSS) score at week 12. Secondary outcomes were improvement in bloating and change in gut microbiota at week 12. After 12‐week follow‐up, those in the placebo group were assigned to receive open‐label FMT.

Results

At week 12, 57.1% in the FMT group and 46.4% in the placebo group achieved the primary endpoint ( p = 0.42). More patients receiving FMT than placebo had improvement in bloating (72% vs 30%; p = 0.005). In an open‐label extension, 65.2% and 82.4% of patients achieved, respectively, the primary endpoint and improvement in bloating. Faecal microbiome of patients in the FMT group showed a reduction in bacteria like Ruminococcus gnavus and enrichment of bacteria such as Lawsonibacter at week 12, while no change in the placebo group. Functional analyses showed that the hydrogen sulphide‐producing pathway decreased in patients who had FMT ( p < 0.05) accompanied by a reduction in contributing bacteria. There were no serious adverse events related to FMT.

Conclusion

FMT performed twice at an interval of four weeks did not significantly reduce IBS‐SSS score. However, more patients had improvement in abdominal bloating, which was associated with a reduction in hydrogen sulphide‐producing bacteria. ( ClinicalTrials.gov NCT03125564).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromeHydrogen SulfideHumansFecal Microbiota TransplantationDiarrheaFecesTreatment Outcome

Substanzen

Hydrogen Sulfide

Autor:innen und Institutionen

  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Microbiota I-Center (MagIC), Hong Kong SAR, China.
  • Li Ka Shing Institute of Health Sciences, State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Microbiology, The Chinese University of Hong Kong, Hong Kong SAR, China.

ORCID-Profile: Siew C Ng

Förderung

  • Health and Medical Research Fund

Zitieren

APA

Yau, Y. K., Su, Q., Xu, Z., Tang, W., Ching, J. Y. L., Mak, J. W. Y., Cheung, C. P., Fung, M., Ip, M., Chan, P. K. S., Wu, J. C. Y., Chan, F. K. L., & Ng, S. C. (2023). Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea. Alimentary Pharmacology & Therapeutics, 58(8), 795-804. https://doi.org/10.1111/apt.17703

Vancouver

Yau YK, Su Q, Xu Z, Tang W, Ching JYL, Mak JWY, et al. Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea. Alimentary Pharmacology & Therapeutics. 2023;58(8):795-804. doi:10.1111/apt.17703

BibTeX
@article{Yau2023,
  author = {Yau, Yuk Kam and Su, Qi and Xu, Zhilu and Tang, Whitney and Ching, Jessica Y L and Mak, Joyce Wing Yan and Cheung, Chun Pan and Fung, Matthew and Ip, Margaret and Chan, Paul Kay Sheung and Wu, Justin Che Yuen and Chan, Francis Ka Leung and Ng, Siew C},
  title = {Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {58},
  number = {8},
  pages = {795--804},
  doi = {10.1111/apt.17703}
}
Kostenlos starten →